EZH2 and urinary bladder carcinoma: EZH2 activity has been shown to be upregulated in a variety of malignancies, such as breast, prostate, and bladder cancers [57,58], preferentially complicated by osteolytic bone metastasis, in which augmented osteoclast differentiation plays a crucial role [59].